X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (4) 4
humans (4) 4
index medicus (4) 4
male (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer (3) 3
chemotherapy (3) 3
leukemia, myeloid, acute - drug therapy (3) 3
leukemia, myeloid, acute - mortality (3) 3
middle aged (3) 3
treatment outcome (3) 3
abridged index medicus (2) 2
aged (2) 2
antimetabolites, antineoplastic - therapeutic use (2) 2
bone marrow (2) 2
clinical trials (2) 2
cytarabine (2) 2
double-blind method (2) 2
elderly-patients (2) 2
hematology (2) 2
kaplan-meier estimate (2) 2
leukemia (2) 2
life sciences (2) 2
medical prognosis (2) 2
medicine (2) 2
oncology (2) 2
patients (2) 2
recurrence (2) 2
risk myelodysplastic syndromes (2) 2
standards (2) 2
survival (2) 2
5-azacytidine (1) 1
[ sdv ] life sciences [q-bio] (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
[sdv.can]life sciences [q-bio]/cancer (1) 1
acute disease (1) 1
acute myelogenous leukemia (1) 1
acute myeloid leukemia (1) 1
acute myeloid-leukemia (1) 1
adult (1) 1
age factors (1) 1
aged patients (1) 1
aged, 80 and over (1) 1
agmt-study group (1) 1
aml (1) 1
analysis (1) 1
anthracyclines (1) 1
antibiotics, antineoplastic - therapeutic use (1) 1
anticoagulants (1) 1
anticoagulants - administration & dosage (1) 1
anticoagulants - adverse effects (1) 1
anticoagulants - therapeutic use (1) 1
antimetabolites, antineoplastic (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - toxicity (1) 1
apheresis (1) 1
azacitidine (1) 1
azacitidine - administration & dosage (1) 1
azacitidine - therapeutic use (1) 1
biochemistry (1) 1
blast crisis (1) 1
blast crisis - drug therapy (1) 1
blast crisis - pathology (1) 1
blood clots (1) 1
bone-marrow (1) 1
brain cancer (1) 1
cancer treatment (1) 1
cancers and neoplasms (1) 1
cardiovascular disease (1) 1
cd34 antigen (1) 1
cell biology (1) 1
chemotherapy and drug treatment (1) 1
chemotherapy, adjuvant (1) 1
chronic myelomonocytic leukemia (1) 1
classification (1) 1
colony-stimulating factor (1) 1
combination (1) 1
consolidation (1) 1
consolidation chemotherapy (1) 1
constraining (1) 1
conventional care regimens (1) 1
cytarabine - administration & dosage (1) 1
cytarabine - therapeutic use (1) 1
daunorubicin (1) 1
daunorubicin - administration & dosage (1) 1
daunorubicin - therapeutic use (1) 1
deoxyribonucleic acid (1) 1
deoxyribonucleic acid--dna (1) 1
diagnosis (1) 1
disease progression (1) 1
disease-free survival (1) 1
dna (1) 1
dna methylation (1) 1
dnmt3a mutations (1) 1
double-blind (1) 1
drug dosages (1) 1
drug therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2012, Volume 7, Issue 12, pp. e52695 - e52695
Introduction: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in... 
CONVENTIONAL CARE REGIMENS | PROGNOSTIC IMPACT | IDH2 MUTATIONS | 5-AZACYTIDINE | RECOMMENDATIONS | MULTIDISCIPLINARY SCIENCES | TET2 | RISK MYELODYSPLASTIC SYNDROMES | DNMT3A MUTATIONS | INDUCTION | CHRONIC MYELOMONOCYTIC LEUKEMIA | Humans | Middle Aged | Induction Chemotherapy | Male | Treatment Outcome | Consolidation Chemotherapy | Cytarabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - toxicity | Feasibility Studies | Leukemia, Myeloid, Acute - mortality | Maximum Tolerated Dose | Pilot Projects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Daunorubicin - administration & dosage | Azacitidine - administration & dosage | Anthracyclines | Chemotherapy | Analysis | Oncology, Experimental | Clinical trials | Aged patients | Research | Standards | Cancer | Toxicity | Leukemia | Brain cancer | Oncology | Cardiovascular disease | Kinases | Randomization | Cytarabine | Daunorubicin | Consolidation | Safety engineering | DNA methylation | Bone marrow | Remission | Heart diseases | Drug dosages | Deoxyribonucleic acid--DNA | Medical research | Hematology | Myeloid leukemia | Feasibility studies | Patients | Survival | Constraining | White blood cells | Medicine | Medical prognosis | Mutation | Acute myeloid leukemia | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 03/2018, Volume 53, Issue 3, pp. 246 - 254
High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard of care in different hematologic malignancies. The goal of... 
CD34 antigen | Apheresis | Transplantation | Lymphoma | Patients | Hematopoietic stem cells | Infusion | Chemotherapy | Granulocyte colony-stimulating factor | Peripheral blood | Stem cells | Colony-stimulating factor | Leukocytes (granulocytic) | Life Sciences | Cancer
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.